Outcome measures in the lung
Open Access
- 10 September 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 47 (Supplement), v48-v50
- https://doi.org/10.1093/rheumatology/ken311
Abstract
The indolent progression of lung disease in SSc has caused great difficulty in therapeutic studies as outcome measures need to be sensitive. Idiopathic pulmonary fibrosis (IPF) has been more widely studied and can usefully be extrapolated to SSc, but is more rapidly progressive. In IPF, forced vital capacity (FVC) trends are the most accurate serial surrogate for mortality. Serial gas transfer trends have a lower prognostic value in IPF and may be confounded by pulmonary vascular disease in SSc. Unresolved issues include the optimal time interval between pulmonary function tests and the mode of expression of change (percentage change from baseline vs absolute change). It has yet to be determined whether changes in pulmonary function variables are best analysed continuously or categorically (i.e. according to whether a threshold for ‘significant change’ has been reached). The 6-min walk distance has proved disappointing as an outcome variable due to major inter-test variability over the course of therapeutic studies, ascribable to extra-pulmonary factors. Serial CT is promising in principle but an optimal scoring system has proved elusive. Dyspnoea and quality of life scales provide useful ancillary information as to the likelihood that pulmonary function trends are clinically significant. For the time being, serial change in FVC appears to be the best primary end-point.Keywords
This publication has 12 references indexed in Scilit:
- BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis & Rheumatism, 2006
- Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testAnnals Of The Rheumatic Diseases, 2006
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2005
- Six-Minute Walk, Maximal Exercise TestsAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Fibrotic Idiopathic Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to OutcomeAmerican Journal of Respiratory and Critical Care Medicine, 2002